StreetAlpha.app
Home › Stocks › AARD

Aardvark Therapeutics, Inc. (AARD)

$0.92
▼ −7.74%
LAST CLOSE · NOV 20

Aardvark Therapeutics is a San Diego biopharmaceutical company developing oral medicines that aim to reduce hunger in metabolic conditions. It last closed at $0.92 on Nov 20, down 7.74% on the day. The next earnings report for AARD is expected around Mon, Mar 22, 2027, after the close. For the quarter ended Sep 2026, AARD reported EPS of -$0.88 on revenue of $0. Over its last 8 reports the stock moved an average of 7.1% the session after earnings. Over the last 12 months AARD insiders bought $145K of stock on the open market and sold $395K, according to SEC Form 4 filings.

AI Auto Pilots
Is AARD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold AARD.

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$72.8M
EPS (diluted)
−$3.33
Free cash flow
−$66.8M
Valuation
Market cap
$20.2M
21.9M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$60.3M
At Sep 30
Shareholder equity
$57.6M
Shares outstanding
21.9M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: −$20.6M−$20.6MFY2024FY2025: −$57.6M−$57.6MFY2025

From AARD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Next report
Mar 22
Estimated date · After the close
Reported EPS
-$0.88
Quarter ended Sep 2026
Year ago EPS
-$0.75
Same quarter last year
Revenue
$0
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$2.18Dec '24Mar 2025: -$0.71Mar '25Jun 2025: -$0.66Jun '25Sep 2025: -$0.75Sep '25Dec 2025: -$0.81Dec '25Mar 2026: -$0.99Mar '26Jun 2026: -$0.66Jun '26Sep 2026: -$0.88Sep '26Latest -$0.88
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $0Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Mar 2026: $0Mar '26Jun 2026: $0Jun '26Sep 2026: $0Sep '26Latest $0
How AARD moved after its last 8 reports
Average move the session after a report ±7.1%
Nov 13, 2026Time not announced−12.5%
Aug 11, 2026After the close−8.6%
May 7, 2026Time not announced−4.9%
Mar 23, 2026After the close−7.3%
Nov 13, 2025After the close−8.7%
Aug 13, 2025After the close+0.5%
May 14, 2025After the close+4.0%
Mar 31, 2025After the close+10.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on AARDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on AARD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on AARD

Technical Analysis

AARD · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 36% below its 20 day and 263% below its 50 day average. It is 481% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $0.90, and the nearest resistance the Pivot at $0.96.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 34.7%/day
Key levels
$16.6052 week high+1704.3%
$5.36200 day average+482.6%
$4.82100 day average+423.9%
$3.3550 day average+264.1%
$1.70Swing high (Nov 13)+84.8%
$1.2520 day average+35.9%
$1.02Pivot R1+10.9%
$0.96Pivot+4.3%
$0.92Last close
$0.9052 week low−2.2%
$0.86Pivot S1−6.5%
Indicators
RSI (14)28.66Oversold below 30Oversold
MACD-0.65Above its signal lineBullish
Stochastic5.0Near the bottom of its rangeOversold
ADX (14)43.8Strong downtrend
Williams %R-97.2Oversold below −80, overbought above −20Oversold
CCI (20)-153.1Oversold below −100, overbought above 100Oversold
Rate of change−21.1%Change over 10 sessionsBearish
ATR (14)$0.32Typical daily range, 34.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for AARD

What happened before

See how AARD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for AARDHow many large options trades hit AARD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

AARD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●35 buying vs 37 selling
  • ●Held by funds -0.0 pts
  • ▲Funds holding +4
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding7672+5.6%
In funds' top 10110.0%
Held by funds43.6%43.6%−0.0 pts
New / increased14 / 2119 / 20−10.3%
Reduced / sold out27 / 1024 / 24−22.9%
Put/call ratio–0.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AARD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AARD Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$145K2 buys · 2 insiders
Sold$395K1 sale · 1 insider
100% of the selling was under pre-arranged trading plans.
Cluster buy: 2 insiders bought $145K between Dec 11 and Dec 11.
2025-12 bought $145K2026-09 sold $395KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 11Nelson SunSee RemarksSale plan76,754$5.15$395K
Dec 11, 2025Tien-Li LeeCEOBuy7,000$14.49$101K
Dec 11, 2025Nelson SunCFOBuy3,000$14.40$43K
Sep 15, 2025Tien-Li LeeCEOBuy10,000$9.66$97K
Sep 12, 2025Tien-Li LeeCEOBuy20,000$8.03$161K
Sep 9, 2025Nelson SunCFOBuy6,000$8.07$48K
Every insider buy and sale for AARD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See AARD insider trades →

From SEC Form 4 filings by AARD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AARD is in one of them and how their past AARD trades turned out.

AARD in the AI portfolios
Loading…

AARD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AARD in an article yet. Here's the latest on the wider market.

AARD in the news

About Aardvark Therapeutics

Aardvark Therapeutics is a biopharmaceutical company based in San Diego, California, that develops small molecule medicines aimed at reducing hunger. Its work centers on compounds that act on bitter taste receptors in the gut, which are designed to prompt the body to release its own appetite-related hormones. Its lead candidate, ARD-101, is an oral drug being studied for hyperphagia, an extreme hunger condition associated with Prader-Willi syndrome. The company has no approved products yet and aims to serve patients with metabolic conditions and the clinicians who treat them.

Headquarters
San Diego, CA